Skip to main content
. 2023 Nov 7;14:1215755. doi: 10.3389/fendo.2023.1215755

Table 1.

Study characteristics.

Study Year Sample size (n) Age (year) Duration of infertility (year) BMI (kg/m2) GH dose Stimulation protocol Outcomes
T/C T C T C T C
He (20) 2023 32/32 33 (32, 37) 34 (31, 38) 4.5(2.0,7.3) 2(1.0, 5.3) 20.7(19.9, 21.8) 20.9(19.5, 23.3) 3 IU/d Minimal stimulation protocol ②⑦⑩
Shi (13) 2022 48/48 36.15 ± 3.02 36.73 ± 2.85 4.08 ± 1.35 4.11 ± 1.37 23.30 ± 2.11 23.31 ± 2.01 4 IU/d GnRH antagonist protocol ①②③⑥⑦⑧⑨⑩⑪⑫⑬
Wei (21) 2022 24/24 40.36 ± 2.24 40.23 ± 2.18 NA NA NA NA 4 IU/d GnRH antagonist protocol ②③⑥⑦
Xin (23) 2022 37/37 27.75 ± 2.02 27.93 ± 2.14 4.30 ± 0.49 4.27 ± 0.45 22.06 ± 2.16 22.13 ± 2.01 4 IU/d GnRH antagonist protocol ①②③⑨⑩⑪⑫⑬
Kang (15) 2020 36/38 39.63 ± 4.85 40.15 ± 4.69 5.17 ± 1.72 5.21 ± 1.70 NA NA 5 IU/d GnRH antagonist protocol ①②⑤⑧⑨⑩⑪⑫⑬
Tang (25) 2019 40/42 31.0 ± 3.0 30.0 ± 3.0 4.0 ± 2.5 3.6 ± 2.3 21.7 ± 2.6 22.8 ± 3.6 5 IU/d Short GnRH agonist protocol ①②⑩⑫⑬
Wang (22) 2018 45/44 38.21 ± 3.95 38.19 ± 3.93 NA NA NA NA 4.51 IU/d GnRH antagonist protocol ①②③⑥⑦⑩⑫⑬
Zhang (16) 2018 60/60 37.42 ± 1.19 37.91 ± 1.75 5.64 ± 2.80 5.92 ± 2.16 NA NA NA Short GnRH agonist protocol ①②③⑤⑥⑦⑨
Zhao (14) 2017 50/50 38.25 ± 4.52 37.38 ± 4.75 NA NA NA NA 4.5 IU/d GnRH antagonist protocol ②③⑩⑪⑫⑬
Lin (24) 2017 55/50 36.62 ± 3.17 37.42 ± 3.23 NA NA 23.31 ± 3.73 23.09 ± 3.79 4.5 IU/d Long GnRH agonist protocol ①②③⑤⑧⑨⑩⑪⑫⑬

T, trial group; C, control group; BMI, body mass index; GH, growth hormone; NA, not available; GnRH, gonadotropin-releasing hormone; ① Clinical pregnancy rate; ② Number of oocytes retrieved; ③ Optimal embryos rate; ④ Number of optimal embryos; ⑤ Cycle cancellation rate; ⑥ Cleavage rate; ⑦ Fertilization rate; ⑧ Embryo implantation rate; ⑨ Miscarriage rate; ⑩ E2 levels on the day of hCG; ⑪ Endometrial thickness on the day of hCG; ⑫ Total days of Gn used; ⑬ Total dose of Gn used.